Page 1

EX - 99.1 2 osur - 20210803 ex99 1.htm EX - 99.1 OraSure Technologies , Inc. EXHIBIT 99.1 Investor Contact : Scott Gleason SVP Investor Relations & Corporate Communications 484-425-0588 sgleason@orasure.com Media Contact : Amy Koch Sr. Mgr . Corporate Communications 484-353-1815 media@orasure.com OraSure Technologies Reports 2Q21 Revenue of $ 57.6 Million Driven by Strong Rebound in Core Business Excluding COVID - 19 product revenues , revenues for the second quarter grew 122 % YoY and 48 % sequentially as the Company's core business began to return to pre - pandemic revenue levels Company received three Emergency Use Authorizations ( EUAs ) from the U.S. Food and Drug Administration ( FDA ) for its InteliSwab ™ COVID - 19 Rapid Tests for Non - Prescription ( OTC ) , Professional Point - of - Care and Prescription Home Use Management to Host Analyst / Investor Call and Webcast Today at 5:00 p.m. ET BETHLEHEM , PA , August 3 , 2021 ( GLOBE NEWSWIRE ) -- OraSure Technologies , Inc. ( NASDAQ : OSUR ) , a leader in point - of - care and home diagnostic tests , specimen collection devices , and microbiome laboratory and analytical services , today announced its financial results for the three months ended June 30 , 2021 . " This quarter , OraSure once again demonstrated strong financial performance highlighted by a recovery in our core business as the Company began to return to pre - pandemic revenue levels . Importantly , we have now received three EUAs for our InteliSwab ™ COVID - 19 Rapid Tests , signed up two major distributors , and established a significant pipeline of sales inquiries . This represents a significant achievement as we continue to demonstrate the ability of the Company to develop and launch new products , " said Stephen Tang , Ph.D. , President and CEO of OraSure Technologies . Dr. Tang continued , “ As we look to the second half of the year we believe the business is well positioned for year - over - year growth given the commercial launch of InteliSwab ™ We are responding to strong global customer interest for InteliSwab ™ tests and anticipate exiting the year at a significant revenue run rate . Newer areas such as our microbiome kits and services business are becoming increasingly important to our growth story and achieved record revenue in the second quarter . Overall , we are highly focused on spurring innovation , strengthening our product pipeline , and deploying capital through strategically sound acquisitions that leverage our commercial infrastructure to drive long - term sustained growth and value for our stockholders . " Financial Highlights □ Net revenues for the second quarter of 2021 were $ 57.6 million , a 97 % increase from the second quarter of 2020 . Excluding COVID - 19 product revenues , revenues for the quarter increased 122 % YoY and 48 % sequentially as the company began to return to pre - pandemic revenue levels . 1